2013 | 2012 | 2011 | 2010 | 2009 | 2008
2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000
Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013; 158:84-92. Link
Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, Keatinge J, Park JE, Maruva M, Cerda R, Wood R, Dabis F, Freedberg KA. Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Clin Infect Dis. 2013; 53:430-46. Link
Levison J, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, Freedberg KA, Wood R. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance from a large HIV treatment program in South Africa. PLoS One. 2012; 7:e32144. Link
Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky PR. Genotype assays and third-line ART in resource-limited settings: A simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012; 26:1083-93.Link
Bassett IV, Chetty S, Wang B, Mazibuko M, Giddy J, Lu Z, Walensky RP, Freedberg KA, Losina E. Loss to follow-up and mortality among HIV-infected people co-infected With TB at ART initiation in Durban, South Africa. JAIDS. 2012; 59:25-30.Link
Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials. 2012; 13:1-10.Link
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR 3rd, Paltiel AD. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012; 54:1504-13Link
Anglaret X, Scott C, Walensky RP, Outtara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholie S, Freedberg K. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2012; doi:10.3851/IMP2231 [Epub ahead of print].Link
Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, Walensky RP. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012; 26:987-95Link
Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of Progression to Active Tuberculosis Following Reinfection With Mycobacterium tuberculosis. Clin Infect Dis. 2012 [Epub ahead of print] Link
Ahonkhai AA, Noubary F, Munro, A, Stark R, Wilke M, Freedberg KA, Wood R, Losina E. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012; 7:e32993.Link
Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute Hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012; 55:279-290.Link
Kranzer K, Govindasamy D, van Schaik N, Thebus E, Davies N, Zimmermann M, Jeneker S, Lawn S, Wood R, Bekker LG. Incentivized recruitment of a population sample to a mobile HIV testing service increases the yield of newly diagnosed cases, including those in need of antiretroviral therapy. HIV Med. 2012; 13:132-7.
Link
Schackman BS, Metsch L, Colfax GN, Leff JA, Wong AY, Scott CA, Feaster DJ, Gooden L, Matheson T, Mandler R, Haynes LF, Paltiel AD, Walensky RP. The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. Drug Alcohol Depend. 2012; Epub ahead of print.Link
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y, Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012; 26:45-56. Link
Andrews JR, Wood R, Bekker LG, Middelkoop K, Walensky RP. Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care. J Inf Dis. 2012; 206:543-51.Link
Arbelaez C, Wright EA, Losina E, Millen JC, Kimmel S, Dooley M, Reichmann WM, Mikulinsky R, Walensky RP. Emergency Provider Attitudes and Barriers to Universal HIV Testing in the Emergency Department. J Emerg Med. 2012; 42:7-14.Link
Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, Walensky RP. The cost-effectiveness of tuberculosis preventive therapy for HIV-Infected individuals in southern India: a trial-based analysis. PLoS One. 2012; 7:e36001. Link
Ouattara EN, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012; 26:625-34.Link
Donnell-Fink LA, Arbelaez C, Collins JE, Novais A, Case A, Pisculli ML, Reichmann WM, Katz JN, Losina E, Walensky RP. Acceptability of fingerstick vs. oral fluid rapid HIV testing: results from the universal screening for HIV-infection in the emergency room (USHER-Phase II) randomized controlled trial. J Acquir Immune Defic Syndr. 2012; [Epub ahead of print].Link
Reichmann WM, Walensky RP, Case A, Novais A, Arbelaez C, et al. Estimation of the prevalence of undiagnosed and diagnosed HIV in an urban emergency department. PLoS One. 2012; 6:e27701. Link
Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, Lawn SD, Wood R, Bekker LG. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis. 2012; 12:21. Link
Ciaranello AL, Perez F, Keatinge J, Park J, Engelsmann B, Maruva M, Walensky RP, Dabis F, Chu J, Rusibamayila A, Mushavi A, Freedberg KA. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. Plos Med. 2012; 9:e1001156.Link
Hom JK, Wang B, Chetty S, Giddy J, Mazibuko M, Allen J, Walensky RP, Losina E, Freedberg KA, Bassett IV. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa. PLoS One. 2012; 7:e43281. Link
Ramirez-Avila L, Regan S, Giddy J, Chetty S, Ross D, Katz JN, Freedberg KA, Walensky RP, Losina E, Bassett IV. Depressive symptoms and their impact on health-seeking behaviors in newly-diagnosed HIV-infected patients in Durban, South Africa. 2012. AIDS Behav. Epub 2012.Link
Morrow C, Munro A, Wilke M, Stark R, Wood R. Remote sensing of HIV care programmes using centrally collected laboratory results: can we monitor ART programme effectiveness? S Afr Med J. 2012; 102:501-5.Link
Levison JH, Wood R, Scott CA, Ciaranello AL, Martinson NA, Rusu C, Losina E, Freedberg KA, Walenskey RP. The Clinical and Economic Impact of Genotype Testing at First-line Antiretroviral Therapy Failure for HIV-infected Patients in South Africa. Clinical Infectious Diseases. 2012; doi: 10.1093/cid/cis887Link
Shenoy ES, Walensky RP, Lee H, Orcutt B, Hooper DC. Resource Burden Associated with Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus: The Patient Access Managers' Perspective. Infect Control Hosp Epidemiol 2012; 33(8): 849-52. Link
Shenoy ES, Hsu H, Noubary F, Hooper DC, Walensky RP. National Survey of Infection Preventionists: Policies for Discontinuation of Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Infect Control Hosp Epidemiol 2012; 33(12): 1272-5. Link
Morrow C, Munro A, Wilke M, Stark R, Wood R. Remote sensing of HIV care programmes using centrally collected laboratory results: can we monitor ART programme effectiveness? S Afr Med J. 2012; 102:501-5.Link
Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; The ANRS 12222 Morbidity/Mortality Study Group. AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in Cote d'Ivoire. Clin Infect Dis. 2012; 54:714-72 Link
April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. J Gen Intern Med. 2011; 26:661-7 Link
Bassett I, Chetty S, Giddy J, Reddy S, Bishop K, Lu Z, Losina E, Freedberg K, Walensky R. Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med. 2011; 12:46-53 Link
Chu J, Sloan CE, Freedberg KA, Yazdanpanah Y, Losina E. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. AIDS Res Ther. 2011; 8:14 Link
Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP, CEPAC-International and OCTANE Investigators. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011; 25:479-92 Link
Ciaranello AL, Perez F, Maruva M, Chu J, Engelsmann B, Keatinge J, Walensky RP, Mushavi A, Mugwagwa R, Dabis F, Freedberg KA; CEPAC-International Investigators. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One. 2011; 6(6):e20224 Link
Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011; 9:59. Link
Hsu H, Rydzak C, Cotich K, Wang B, Sax P, Losina E, Freedberg K, Goldie S, Lu Z, Walensky R; for the CEPAC Investigators. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011; 12:97-108 Link
Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011; 18:506-12 Link
Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011; 56:356-64 Link
Messou E, Kouakou M, Gabillard D, Gouessé P, Koné M, Tchehy A, Losina E, Freedberg KA, Dri-Yoman TN, Anzian A, Toure S, Anglaret X. Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'Ivoire. J Acquir Immune Defic Syndr. 2011; 1;57 Suppl 1:S34-9 Link
Pisculli ML, Reichmann WM, Losina E, Donnell-Fink LA, Arbelaez C, Katz JN, Walensky RP. Factors associated with refusal of rapid HIV testing in an emergency department. AIDS Behav. 2011 ; 15:734-42. Link
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD, Cost-Effectiveness of Preventing AIDS Complications-International Investigators. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011; 56:26-35 Link
Wang B, Losina E, Stark R, Munro A, Walensky RP, Wilke M, Martin D, Lu Z, Freedberg KA, Wood R. Loss to follow-up in a community clinic in South Africa roles of gender, pregnancy and CD4 count. S Afr Med J. 2011; 101:253-257 Link
Bassett I, Regan S, Chetty S, Giddy J, Uhler L, Holst H, Ross D, Katz J, Walensky R, Freedberg KA, Losina E. Who starts ART Durban, South Africa?... not everyone who should. AIDS. 2010; 24 Suppl 1:S37-44. Link
Bassett IV, Walensky RP. Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S77-84. Link
Bender M, Kumarasamy N, Mayer K, Wang B, Walensky R, Flanigan T, Schackman B, Scott C, Lu Z, Freedberg KA. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010; 50:416-25. Link
Kimmel A, Weinstein M, Anglaret A, Goldie S, Losina E, Yazdanpanah Y, Messou E, Cotich K, Walensky R, Freedberg KA. Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness. J Acquir Immune Defic Syndr. 2010; 54:258-68 Link
Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2010 Jun 9. [Epub ahead of print] Link
Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, Ross D, Scott CA, Uhler LM, Katz JN, Holst H, Freedberg KA. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010; 5:e9538. Link
Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y. Economic evaluation of ART in resource-limited countries. Curr Opin HIV AIDS. 2010 May; 5:225-31. Link
Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S, Losina E, Freedberg KA, Danel C, Anglaret X, Yazdanpanah Y. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One. 2010; 5:e13414 Link
Robbins G, Johnson K, Chang Y, Jackson K, Sax P, Meigs J, Freedberg KA. Predicting virologic failure in an HIV clinic. Clin Infect Dis. 2010; 50:779-786. Link
Rydzak CE, Cotich KL, Sax PE, Hsu HE, Wang B, Losina E, Freedberg KA, Weinstein MC, Goldie SJ, CEPAC Investigators. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010; 5: e12647 Link
Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA, Cepac US And Actg A5164 Investigators. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials. 2010; 11 :248-59
Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, Stoler AW, Lu Z, Walensky RP, Flanigan TP, Bender MA, Freedberg KA, Swaminathan S, CEPAC International investigators. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One. 2010; 5: e12747 Link
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA, CEPAC Investigators. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010; 51:392-400. Link
Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA, CEPAC-International Investigators. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010; 7:e1000382 Link
Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis. 2010 Jul 1; 51:85-92. Link
Walensky RP, Kuritzkes DR. The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential. Clin Infect Dis. 2010 Jan 15; 50:272-5. Link
Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, Danel C, Sloan CE, Losina E, Freedberg KA; CEPAC-International Investigators. CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antivir Ther. 2010; 15:351-61. Link
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 2010; 5:e13132 Link
April MD, Walensky RP, Chang Y, et al. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr 2009;51:310-6. Link
Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009;51:135-9. Link
Ciaranello AL, Chang Y, Margulis AV, Bernstein A, Bassett IV, Losina E, Walensky RP. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009; 49:1915-27. Link
Ciaranello AL, Walensky RP, Sax PE, Chang Y, Freedberg KA, Weissman JS. Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. HIV Clin Trials 2009;10:13-24. Link
Ganguli I, Bassett IV, Dong KL, Walensky RP. Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep. 2009 Nov;6(4):217-23.
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009;49(10):1579-81. Link
Linas BP, Losina E, Rockwell A, Walensky RP, Cranston K, Freedberg KA. Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr 2009;51:513-21. Link
Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009;14:523-31. Link
Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009;48:806-15. Link
Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009;151:157-66. Link
Bassett IV, Farel C, Szmuilowicz ED, Walensky RP. HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis 2008;47:695-701.
Bassett IV, Giddy J, Wang B, et al. Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med 2008;9:863-7.
Ciaranello AL, Seage GR, 3rd, Freedberg KA, Weinstein MC, Lockman S, Walensky RP. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS 2008;22:2359-69.
Jean-Jacques M, Walensky RP, Aaronson WH, Chang Y, Freedberg KA. Late diagnosis of HIV infection at two academic medical centers: 1994-2004. AIDS Care 2008;20:977-83.
Losina E, Figueroa P, Duncan J, et al. HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993 2005. Int J Infect Dis 2008;12:132-8.
Millen JC, Arbelaez C, Walensky RP. Implications and Impact of the New US Centers for Disease Control and Prevention HIV Testing Guidelines. Curr Infect Dis Rep 2008;10:157-63.
Ojikutu BO, Zheng H, Walensky RP, et al. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J 2008;98:204-8.
Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-33.
Valerio L, Yazdanpanah Y, Poizot-Martin I, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2008;47:50-5.
Walensky RP, Freedberg KA, Weinstein MC. Monitoring of antiretroviral therapy in low-resource settings. Lancet 2008;372:288; author reply 9.
Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008;197:1324-32.
Campos N, Salomon JA, Nunes MD, Samet J, Freedberg KA, Goldie SJ. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with human immunodeficiency virus. Am J Med 2007; 120:272-9
Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and care in the United States. Clin Infect Dis 2007; 45 Suppl4:S248-S254.
Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV regimen simplification: A simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45: 1062-70.
Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA. Beyond short term virologic suppression, the long term benefits of genotypic resistance testing in patients with extensive prior antiretroviral: a model based approach. HIV Med 2007; 7: 439-50.
McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage III GR. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 2007; 44: 1115-1122.
Wolf LL, Walensky RP. Testing for HIV infection in the United States. Current Inf Dis Rep 2007; 9: 76-82.
Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19.
Liddicoat RV, Losina E, Kang M, Freedberg KA, Walensky RP. Refusing HIV testing in an urgent care setting: Results from the Think HIV program. AIDS Patient Care & STDs 2006; 20: 84-92.
Linas BP, Zheng H, Losina E, Walensky RP, Freedberg KA. Assessing the impact of federal HIV prevention spending on HIV testing and awareness. Am J Public Health 2006; 96: 1038-43.
Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanpanah Y, Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials 2006; 7: 59-69.
Linas BP, Zheng H, Losina E, Rockwell A, Walensky RP, Cranston K, Freedberg KA. Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis 2006;43:1357-64.
Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage III GR, Moore RD, Freedberg KA. The lifetime cost of current HIV care in the Unites States. Med Care 2006; 44: 990-997.
Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. J Acquir Immune Defic Syndr 2006; 43 (supplement 1): S113-118.
Liddicoat RV, Zheng H, Internicola J, Werner BG, Kazianis A, Golan Y, Rubinstein EP, Freedberg KA, Walensky RP. Implementing a Routine, Voluntary HIV Testing Program in a Massachusetts County Prison. J Urban Health 2006; 83: 1127-31.
Paltiel AD, Walensky RP, Schackman BR, Seage III GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: Effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145: 797-806.
Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? Ann Intern Med 2006; 145: 459-62.
Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther 2005; 10:42-52.
Paltiel AD, Weinstein MC, Kimmel AD, Seage III GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded screening for HIV in the United States: An analysis of cost-effectiveness. N Engl J Med. 2005; 352:586-595.
Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr 2005; 38:163-173.
Samet JH, Horton NJ, Meli S, Dukes K, Tripp T, Sullivan L, Freedberg KA. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antiviral Therapy 2005; 10:83-93.
Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-1323.
Sax PE, Losina W, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-effectiveness of Enfuvirtide (ENF) in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 2005; 39:69-77.
Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid section 115 demonstrations for early HIV treatment in Georgia and Massachusetts. Health Care Financ Rev 2005; 26:67-80.
Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L, for the Center for Adherence Support and Evaluation (CASE) team. The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS Care 2005; 17:927-937.
Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of screening dollars: The example of HIV counseling, testing and referral. Med Decis Making 2005; 25:321-329.
Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA. Routine HIV testing: An economic evaluation of current guidelines. Am J Med 2005; 118:292-300.
Walensky RP, Losina E, Malatesta L, Barton GE, O'Connor CA, Skolnik PR, Hall JM, McGuire JF, Freedberg KA. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Pub Health 2005; 95:71-3.
Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kimmel AD, Zhang H, N'Dri-Yoman T, Salamon R, Kaplan J, Freedberg K. Clinical impact and cost-effectiveness (C-E) of co-trimoxazole (CTX) prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-1308.
Losina E, Islam R, Pollock AC, Sax PE, Freedberg KA, Walensky RP. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis 2004; 38:1613-1622.
Schackman BR, Oneda K, Goldie SJ. The cost-effectiveness of elective cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. AIDS 2004; 18:1827-1834.
Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? PharmacoEconomics 2004; 22:293-300
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage III GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: How good is good enough? Vaccine 2004; 22:4044-4053.
Walensky RP, Freedberg KA, Losina E, Skolnik PR, Hall JM, Malatesta L, Barton GE, O'Connor CA, McGuire JF. Voluntary HIV testing as part of routine medical care - Massachusetts, 2002. MMWR 2004; 53:523-526.
.
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003; 115:632-641.
Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36:652-662.
Mrus JM, Yi MS, Freedberg KA, Wu AW, Zackin R, Gorski H, Tsevat J. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making 2003; 23:414-421.
Pincus JM, Crosby SS, Losina E, King ER, LaBelle C, Freedberg KA. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis 2003; 37:1699-1704.
Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L, Weinstein MC, Gerard Y, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis 2003; 36:86-96.
Yazdanpanah Y, Goldie SJ, Weinstein MC, Losina E, Lebrun T, Paltiel AD, Seage GR, 3rd, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2003;7:257-266.
Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for HIV-related Pneumocystis carinii pneumonia (PCP): Using simulation modeling to inform clinical guidelines. Arch Intern Med 2002; 162:921-928.
Johri M, Paltiel AD, Goldie SJ, Freedberg KA. The cost-effectiveness of state AIDS Drug Assistance Programs: equity and efficiency in a fragmented financing system. Med Care 2002; 40:429-441.
Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162:2478-2486.
Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. A comparison of HIV/AIDS health state utilities using community and patient preference weights: Implications for cost-effectiveness analyses. Med Decis Making 2002; 22:27-38.
Seage GR, Losina E, Goldie SJ, Paltiel AD, Kimmel AD, Freedberg KA. The role of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts in chronic HIV-1 mortality. J Acquir Immune Defic Syndr 2002; 30:421-428.
Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, 3rd, Losina E, Zhang H, Islam R, Freedberg KA. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr 2002; 31:27-37.
Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis 2002; 35:606-610.
Walensky RP, Losina E, Steger-Craven KA, Freedberg KA. Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med 2002; 162:887-892.
Yazdanpanah Y, Goldie SJ, Weinstein MC, Losina E, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 2002; 7:257-266.
Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DC, Zhang H, Kimmel AD, Goldie SJ. The cost-effectiveness of combination antiretroviral therapy in HIV. N Engl J Med 2001;344:824-31.
Includes editorial by Robert Steinbrook, MDFreedberg KA, Losina E, Goldie SJ. The cost-effectiveness of antiretroviral therapy for HIV disease [letter]. N Engl J Med 2001; 345:68-69.
Freedberg KA, Sullivan LM, Georgakis A, Savetsky J, Stone V, Samet JH. Improving participation in HIV clinical trials: Impact of a brief intervention. HIV Clin Trials 2001; 2:205212.
Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285:3107-3115.
Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost-effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with human immunodeficiency virus. Am J Med 2001; 111:140-149.
Paltiel AD, Goldie SJ, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, Freedberg KA. A pre-evaluation of clinical trial data: The case of pre-emptive CMV therapy in HIV. Clin Inf Dis 2001;32:783-93.
Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of improving access to early antiretroviral therapy among uninsured HIV-infected adults. Am J Publ Hlth 2001;91:1456-63.
Vidrih JA, Walensky RP, Sax PE, Freedberg KA. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med 2001; 111:192-94.
Walensky RP, Rosenberg ES, Ferraro MJ, Losina E, Walker B, Freedberg KA. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Inf Dis 2001; 33:570-72.
Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter J, Zhang H, Kimmel AD, Freedberg KA. Resistance testing to guide the choice of second-line therapy in HIV: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.
Includes editorial by Michael S. Saag, MD
Yazdanpanah Y, Chne, G, Losina E, Soldie SJ, Merchadou, LD, Alfandari S, Seage GR, Sullivan L, Marimoutou C, Paltiel AD, Salamon R, Mouton Y, Freedberg KA. Incidence of primary opportunistic infections in two HIV-infected French clinical cohorts. Int J Epi 2001;30:864-871.
Gross PA, Asch S, Kitahata MM, Freedberg KA, Barr D, Melnick DA, Bozzette SA. Performance measures for guidelines on preventing opportunistic infections in HIV-infected patients. Clin Inf Dis 2000; 30:S85-93.
Kaplan JE, Masur H, Holmes KK, Freedberg KA, Holtgrave D, Piscitelli SC, Van Dyke R, Watts H, and the USPHS/IDSA Prevention of Opportunistic Infections Working Group. An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin Inf Dis 2000; 30:S15-28.